The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The fund aims at investing in companies that extends human healthspan
The product will be commercialized from Unichem's Ghaziabad plant
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
Subscribe To Our Newsletter & Stay Updated
